BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16476447)

  • 1. K644E/M FGFR3 mutants activate Erk1/2 from the endoplasmic reticulum through FRS2 alpha and PLC gamma-independent pathways.
    Lievens PM; Roncador A; Liboi E
    J Mol Biol; 2006 Mar; 357(3):783-92. PubMed ID: 16476447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
    Harada D; Yamanaka Y; Ueda K; Nishimura R; Morishima T; Seino Y; Tanaka H
    Bone; 2007 Aug; 41(2):273-81. PubMed ID: 17561467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCĪ³1/Src-mediated paxillin hyperphosphorylation.
    Montone R; Romanelli MG; Baruzzi A; Ferrarini F; Liboi E; Lievens PM
    Int J Biochem Cell Biol; 2018 Feb; 95():17-26. PubMed ID: 29242050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell adaptation to activated FGFR3 includes Sprouty4 up regulation to inhibit the receptor-mediated ERKs activation from the endoplasmic reticulum.
    Lievens PM; Zanolli E; Garofalo S; Liboi E
    FEBS Lett; 2009 Oct; 583(19):3254-8. PubMed ID: 19761767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient dimerization and interaction with ERGIC-53 occur in the fibroblast growth factor receptor 3 early secretory pathway.
    Lievens PM; De Servi B; Garofalo S; Lunstrum GP; Horton WA; Liboi E
    Int J Biochem Cell Biol; 2008; 40(11):2649-59. PubMed ID: 18577465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.
    Adar R; Monsonego-Ornan E; David P; Yayon A
    J Bone Miner Res; 2002 May; 17(5):860-8. PubMed ID: 12009017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice.
    Iwata T; Li CL; Deng CX; Francomano CA
    Hum Mol Genet; 2001 Jun; 10(12):1255-64. PubMed ID: 11406607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
    Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
    Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum.
    Lievens PM; Liboi E
    J Biol Chem; 2003 May; 278(19):17344-9. PubMed ID: 12624096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
    Naski MC; Wang Q; Xu J; Ornitz DM
    Nat Genet; 1996 Jun; 13(2):233-7. PubMed ID: 8640234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism.
    Su WC; Kitagawa M; Xue N; Xie B; Garofalo S; Cho J; Deng C; Horton WA; Fu XY
    Nature; 1997 Mar; 386(6622):288-92. PubMed ID: 9069288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FRS2-dependent SRC activation is required for fibroblast growth factor receptor-induced phosphorylation of Sprouty and suppression of ERK activity.
    Li X; Brunton VG; Burgar HR; Wheldon LM; Heath JK
    J Cell Sci; 2004 Dec; 117(Pt 25):6007-17. PubMed ID: 15564375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells.
    Nowroozi N; Raffioni S; Wang T; Apostol BL; Bradshaw RA; Thompson LM
    Hum Mol Genet; 2005 Jun; 14(11):1529-38. PubMed ID: 15843401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation.
    Chen J; Williams IR; Lee BH; Duclos N; Huntly BJ; Donoghue DJ; Gilliland DG
    Blood; 2005 Jul; 106(1):328-37. PubMed ID: 15784730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling.
    Lievens PM; Mutinelli C; Baynes D; Liboi E
    J Biol Chem; 2004 Oct; 279(41):43254-60. PubMed ID: 15292251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced binding of FGF1 to mutant fibroblast growth factor receptor 3.
    Khnykin D; Olsnes S
    Growth Factors; 2006 Jun; 24(2):111-9. PubMed ID: 16801131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation.
    Sun CK; Man K; Ng KT; Ho JW; Lim ZX; Cheng Q; Lo CM; Poon RT; Fan ST
    Carcinogenesis; 2008 Nov; 29(11):2096-105. PubMed ID: 18765415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
    Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
    Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.
    Jin M; Yu Y; Qi H; Xie Y; Su N; Wang X; Tan Q; Luo F; Zhu Y; Wang Q; Du X; Xian CJ; Liu P; Huang H; Shen Y; Deng CX; Chen D; Chen L
    Hum Mol Genet; 2012 Dec; 21(26):5443-55. PubMed ID: 23014564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A central nervous system specific mouse model for thanatophoric dysplasia type II.
    Lin T; Sandusky SB; Xue H; Fishbein KW; Spencer RG; Rao MS; Francomano CA
    Hum Mol Genet; 2003 Nov; 12(21):2863-71. PubMed ID: 12966031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.